Pregnancy in polycystic ovary syndrome

Kamalanathan, Sadishkumar; Sahoo, Jaya Prakash; Sathyapalan, Thozhukat

doi:10.4103/2230-8210.107830

Cited by 53 publications

(35 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Unfortunately, pregnancy outcome data are lacking in this specific group of patients. However, in the general PCOS population, the rate of early pregnancy loss (first trimester miscarriage) has been reported to be higher (30-50%) compared to normal women (10-15%) [26]. Hyperandrogenemia, insulin resistance, impaired fibrinolysis, and endometrial dysfunction may explain the high early pregnancy loss rate.…”

Section: Discussionmentioning

confidence: 99%

Type 1 diabetes impairs female fertility even before it is diagnosed

Lin

Chen

Peng

et al. 2018

Diabetes Research and Clinical Practice

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Type 1 diabetes impairs female fertility even before it is diagnosed

Lin

Chen

Peng

et al. 2018

Diabetes Research and Clinical Practice

View full text Add to dashboard Cite

show abstract

“…Известно, что наличие СПКЯ -значимый фактор риска акушерских осложнений (невынашивание беременности, преэклампсия и др.). Так, если в общей популяции частота невынашивания составляет до 15%, то среди беременных с СПКЯ этот показатель может достигать 30-50% [16]. На данном этапе…”

Section: Discussionunclassified

The reserves for improvement of quality of oocytes in polycystic ovarian syndrome

Vartanyan¹,

Цатурова²,

Devyatova³

et al. 2017

Probl. reprod.

View full text Add to dashboard Cite

1 ООО «Клиника вспомогательных репродуктивных технологий «Дети из пробирки», Москва, Россия, 123182; 2 кафедра акушерства, гинекологии и репродуктивной медицины факультета повышения квалификации медицинских работников Российского университета дружбы народов, Москва, Россия, 117198 Цель исследования -оценить эффективность инозита у пациенток с СПКЯ в отношении улучшения качества ооцитов; качество эмбрионов после применения инозита при СПКЯ; исходы циклов ЭКО после терапии инозитом при СПКЯ. Материал и методы. Наблюдательное сравнительное многоцентровое исследование. Критерии включения: возраст <45 лет, перенос эмбрионов (ПЭ) в цикле стимуляции суперовуляции. Критерии исключения: возраст ≥ 45 лет и старше, наличие тяжелой экстрагенитальной патологии, генетических синдромов, сцепленных с Х-хромосомой. Пациентки 1-й группы (n=133) получали инозит 1000 мг + фолиевая кислота 100 мкг (Иноферт, «Humana Pharma International S.p.A.», Nutrilinea S.r.L. для Italfarmaco S.p.A., Италия) на этапе подготовки к ЭКО. 2-ю группу составили 137 пациенток с сохраненным овариальным резервом без СПКЯ, не получавшие инозит до наступления беременности в протоколе ЭКО. Критерии эффективности терапии: количество зрелых ооцитов и эмбрионов хорошего качества, частота наступления беременности на ПЭ, показатель «take home baby», частота невынашивания беременности. Результаты. Количество зрелых ооцитов у женщин 1-й группы было статистически значимо выше, чем во 2-й (р<0,001). Частота наступления беременности на ПЭ (87,0% против 87,4%), показатель «take home baby» (79,6% против 89,4%), частота невынашивания беременности (14,3% против 10,6%) в группах сопоставимы. Выводы. Применение инозита (иноферт, «Humana Pharma International S.p.A.», Nutrilinea S.r.L. для Italfarmaco S.p.A., Италия) у пациенток с СПКЯ в составе прегравидарной подготовки -эффективный метод, позволяющий улучшить качество ооцитов и положительно влияющий на прогноз цикла ЭКО. После лечения отмечаются высокие показатели частоты наступления беременности на ПЭ и «take home baby», что обосновывает целесообразность применения инозита у пациенток с СПКЯ и бесплодием.Objective: -to evaluate the efficacy of inosit donation (Inofert, «Humana Pharma International SpA», Nutrilinea S.r.L. for Italfarmaco SpA, Italy) for improvement of quality of oocytes in PCOS patients; to assess quality of embryos after inosit donation; secondary outcomes of IVF cycles after inosit donation in PCOS women. Design -observational comparative multicenter research. Material and methods. Inclusion criteria: age <45, embryo transfer (ET) at IVF cycle. Exclusion criteria: age ≥45, severe extragenital disease, genetic (X-linked) syndromes. The patients of 1 st group (n=133) were administered inosit 1000 mg + folic acid 100 mkg (Inofert, «Humana Pharma International S.p.A.», Nutrilinea S.r.L. for Italfarmaco S.p.A., Italy), during preconception care. The 137 patients of 2 nd group were not administered inosit before pregnancy. Criteria of efficacy: pregnancy rates per ET, «take home baby», miscarriage rates. Resul...

show abstract

“…So, if in the general population the occurrence of miscarriage is up to 15%, then among pregnant women with PCOS this indicator can reach 30-50% [16]. At this stage, we were not able to collect the information on all the outcomes of IVF cycles, however, based on more than a third of the known outcomes of pregnancies after IVF within the observational study (36.8% in the first group and 34.4% in the second group), it seems possible to assume that the absence of significant differences between the groups in such indicators, as the pregnancy rates per ET (87.0% vs. 87.4%), 'take home baby' (79.6% vs. 89.4%) and low miscarriage rates (14.3% vs. 10.6%), comparable to the population indicators, probably, can be explained, on the one hand, by rational choice of inositol for preconception care at PCOS, and on the other hand -by elimination of luteal phase insufficiency in the course of preconception period and providing adequate luteal phase support in IVF cycles with progesterone administration.…”

Section: Discussionmentioning

confidence: 99%

Improvement in quality of oocytes in polycystic ovarian syndrome in programs of in vitro fertilization

Vartanyan

Цатурова²,

Devyatova³

et al. 2017

Gynecological Endocrinology

View full text Add to dashboard Cite

Inositol therapy is aimed at improving the quality of oocytes during preconception care in patients with polycystic ovarian syndrome (PCOS), a cause of infertility and reproductive dysfunction. The objectives of this observational comparative multicentre study were to evaluate the effectiveness of inositol in improving the quality of oocytes/embryos and IVF cycle outcome. Group 1 patients (N ¼ 133) received inositol 1000 mg (Inofert or Nutrilinea) þ folic acid 0.1 mg. Group 2 consisted of patients with preserved ovarian reserve without PCOS (N ¼ 137), not administered inositol prior to pregnancy. Effectiveness criteria were numbers of mature oocytes and good quality embryos, pregnancy rates per ET, 'take home baby' index and miscarriage rates. Pregnancy rates per ET (87.0% vs. 87.4%), 'take home baby' index (79.6% vs. 89.4%) and miscarriage rates (14.3% vs. 10.6%) were comparable. Use of inositol in patients with PCOS during preconception care is an effective method allowing improvement of oocytes quality and positively affecting IVF cycle prognosis. High pregnancy rates per ET and 'take home baby' index after treatment are justifying inositol usage in patients with PCOS and infertility.ARTICLE HISTORY

show abstract

Pregnancy in polycystic ovary syndrome

Cited by 53 publications

References 60 publications

Type 1 diabetes impairs female fertility even before it is diagnosed

Type 1 diabetes impairs female fertility even before it is diagnosed

The reserves for improvement of quality of oocytes in polycystic ovarian syndrome

Improvement in quality of oocytes in polycystic ovarian syndrome in programs of in vitro fertilization

Contact Info

Product

Resources

About